Acetaminophen And Hydrocodone

Introduction Overview

Generic Name

acetaminophen and hydrocodone

Brand Name

Norco
Lorcet
Hycet
Vicodin and many legacy or generic product names

Dosage Form

Prescription oral tablets and oral solutions containing fixed amounts of hydrocodone bitartrate and acetaminophen.

Drug Class

Opioid analgesic combination; Schedule II controlled substance.

Pharmacokinetics

Absorption:
Both hydrocodone and acetaminophen are absorbed after oral administration. Acetaminophen usually reaches peak concentrations within about 30 to 60 minutes. Hydrocodone peaks later, commonly around 1 to 2 hours depending on product and patient factors.

Distribution:
Hydrocodone crosses the blood-brain barrier and acts in the central nervous system. Acetaminophen distributes widely into body fluids and tissues.

Metabolism:
Hydrocodone is metabolized mainly in the liver by CYP3A4 to norhydrocodone and by CYP2D6 to hydromorphone. Acetaminophen is mainly glucuronidated and sulfated; a small fraction becomes NAPQI, the toxic metabolite responsible for liver injury in overdose.

Elimination:
Hydrocodone and metabolites are eliminated largely in urine. Acetaminophen metabolites are also eliminated mainly in urine. Hepatic impairment, renal impairment, older age, interacting medicines, and overdose risk require extra caution.

Dosage Forms

Available forms:
Products vary by manufacturer but commonly include tablets containing hydrocodone bitartrate 2.5 mg, 5 mg, 7.5 mg, or 10 mg with acetaminophen 300 mg or 325 mg. Oral solutions are also available in product-specific concentrations.

Dosing principles:
Use the lowest effective dose for the shortest duration consistent with the patient's pain severity and treatment goals. Dosing is individualized, and patients must follow the exact prescription label. The total daily acetaminophen from all sources must stay within safe limits.

Missed dose:
If prescribed as needed, take only when needed. If scheduled, follow the prescriber's missed-dose instructions and do not double doses.

Mechanism Of Action

Hydrocodone is a mu-opioid receptor agonist. By activating opioid receptors in the brain and spinal cord, it changes pain perception and emotional response to pain. The same opioid activity can also cause sedation, euphoria, constipation, physical dependence, and respiratory depression.

Acetaminophen provides analgesic and antipyretic effects mainly through central nervous system pathways that reduce prostaglandin-mediated pain and fever signaling. It has little anti-inflammatory activity.

The combination treats pain through two different mechanisms, but the risks also combine: opioid overdose and dependence from hydrocodone, plus liver injury from too much acetaminophen.

Pharmacological Actions

Provides opioid analgesia through mu-opioid receptor activation.
Provides non-opioid analgesic and antipyretic activity through acetaminophen.
Can reduce moderate to severe pain when non-opioid options are inadequate.
Can cause respiratory depression, sedation, constipation, nausea, and physical dependence.
Can cause fatal liver injury if acetaminophen exposure is excessive.

Therapeutic Or Clinical Uses

Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Short-term treatment of selected acute pain when non-opioid analgesics do not provide adequate relief.
Selected chronic pain situations only when benefits outweigh risks and careful monitoring is in place.
Not an appropriate routine cough treatment in this formulation and not a first-line pain medicine when non-opioid options are adequate.

Side Or Adverse Effects

Drowsiness, dizziness, impaired thinking, slowed reaction time, and sedation.
Nausea, vomiting, constipation, dry mouth, and abdominal discomfort.
Respiratory depression, which can be life-threatening or fatal.
Hypotension, fainting, and increased fall risk.
Itching, rash, sweating, and flushing.
Physical dependence, tolerance, opioid use disorder, misuse, addiction, overdose, and death.
Acetaminophen-related liver injury, especially with overdose, alcohol use, liver disease, or use of multiple acetaminophen products.
Serious skin reactions or hypersensitivity from acetaminophen or opioid components.
Adrenal insufficiency, androgen deficiency, or serotonin syndrome in selected settings.
Neonatal opioid withdrawal syndrome after prolonged use during pregnancy.

Precautions

Assess pain severity, non-opioid options, substance use history, respiratory risk, mental health risk, and concurrent sedatives before prescribing.
Use the lowest effective dose and shortest duration.
Monitor closely during initiation and dose increases for sedation and respiratory depression.
Avoid alcohol, benzodiazepines, sedative-hypnotics, muscle relaxants, other opioids, and other CNS depressants unless specifically supervised.
Count acetaminophen from every source, including OTC cold/flu products and other prescription pain medicines.
Use caution in liver disease, kidney disease, older adults, frail patients, sleep apnea, COPD, head injury, or increased intracranial pressure.
Do not stop abruptly after prolonged use; taper gradually under medical supervision.
Store securely away from children, visitors, and anyone for whom it was not prescribed.
Discuss naloxone availability for overdose reversal.

Warnings

Boxed warning: addiction, abuse, and misuse can lead to overdose and death.
Boxed warning: serious, life-threatening, or fatal respiratory depression can occur.
Boxed warning: accidental ingestion, especially by children, can be fatal.
Boxed warning: neonatal opioid withdrawal syndrome can occur with prolonged use during pregnancy.
Boxed warning: CYP3A4 inhibitors, CYP3A4 inducers, or stopping an inducer can dangerously change hydrocodone exposure.
Boxed warning: benzodiazepines or other CNS depressants can cause profound sedation, respiratory depression, coma, and death.
Acetaminophen overdose can cause acute liver failure, liver transplant, or death.
Serotonin syndrome can occur with serotonergic medicines.
MAOIs can intensify opioid effects; avoid use during or within 14 days of MAOI therapy unless specialist-directed.
Driving or operating machinery is unsafe until the patient knows how the medicine affects them.

Contraindication

Significant respiratory depression.
Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment.
Known or suspected gastrointestinal obstruction, including paralytic ileus.
Known hypersensitivity to hydrocodone, acetaminophen, or any product component.

Drug Interactions

Benzodiazepines, alcohol, sedatives, hypnotics, tranquilizers, muscle relaxants, antipsychotics, and other opioids increase CNS and respiratory depression risk.
CYP3A4 inhibitors such as clarithromycin, azole antifungals, and some HIV antivirals can increase hydrocodone exposure.
CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort can lower hydrocodone exposure; stopping an inducer can increase exposure.
CYP2D6 inhibitors can alter hydrocodone conversion to hydromorphone and may change analgesic response.
Serotonergic drugs, including SSRIs, SNRIs, TCAs, triptans, linezolid, lithium, and tramadol, can increase serotonin syndrome risk.
MAOIs can increase opioid toxicity risk and should generally be avoided within 14 days.
Mixed agonist/antagonist opioids and partial agonists can reduce analgesia or precipitate withdrawal.
Warfarin and repeated acetaminophen exposure can increase INR in some patients.
Other acetaminophen-containing products increase liver toxicity risk.

Preparations Of The Drug

Hydrocodone bitartrate/acetaminophen tablets in multiple strengths, commonly paired with 300 mg or 325 mg acetaminophen.
Hydrocodone bitartrate/acetaminophen oral solutions in product-specific concentrations.
Prescription-only Schedule II controlled substance products.
Dispensed with opioid safety labeling and product-specific dosing instructions.
Unused medicine should be disposed of through take-back options or according to FDA disposal guidance for opioids.

Student Key Points

This is an opioid plus acetaminophen, so there are two major toxicity systems: breathing and liver.
Hydrocodone can cause fatal respiratory depression, especially with sedatives or alcohol.
Acetaminophen stacking from multiple products can cause fatal liver injury.
The formal contraindications are narrower than the warning list: respiratory depression, severe unmonitored asthma, GI obstruction, and hypersensitivity.
Naloxone reverses opioid toxicity but does not treat acetaminophen liver toxicity.
N-acetylcysteine treats significant acetaminophen overdose and works best early.